30 March 2020 update:
SGLT2 inhibitors in chronic kidney disease Product Company Study Setting Status Invokana Johnson & Johnson Credence Type 2 diabetics Reported, drug approved Farxiga Astrazeneca Dapa-CKD Diabetics & non-diabetics Halted for efficacy Zynquista Lexicon Scored Type 2 diabetics Halted for lack of funding and Covid-19 lockdown risk, after Sanofi scrapped deal Jardiance Lilly/Boehringer Ingelheim Empa-Kidney Diabetics & non-diabetics Ends mid-2022 Source: EvaluatePharma & clinicaltrials.gov.
30 March 2020 update:SGLT2 inhibitors in chronic kidney...
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
36.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $57.28M | |||
| Open | High | Low | Value | Volume |
| 36.0¢ | 36.5¢ | 35.0¢ | $6.88K | 19.11K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 5 | 6523 | 35.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 36.5¢ | 16375 | 3 |
View Market Depth
| Last trade - 13.03pm 01/08/2025 (20 minute delay) ? |
| PIQ (ASX) Chart |